Craig T Wallington-Beddoe (Craig Wallington-Beddoe, Craig T Wallington-Gates)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Topics

Multiple Myeloma

Systematic Review

Cell Cycle Arrest

Top Venues

International journal of molecular sciences

British journal of haematology

ACS pharmacology & translational science

Journal of hematology & oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Rachel L Mynott, Ali Habib, Oliver Giles Best, Craig T Wallington-Beddoe
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies. International journal of molecular sciences 24 (8) (2023)
Alexander C Lewis, Victoria S Pope, Melinda N Tea, Manjun Li, Gus O Nwosu, Thao M Nguyen, Craig T Wallington-Beddoe, Paul A B Moretti, Dovile Anderson, Darren John Creek, Maurizio Costabile, Saira R Ali, Chloe A L Thompson-Peach, B Kate Dredge, Andrew G Bert, Gregory J Goodall, Paul G Ekert, Anna L Brown, Richard J J D'Andrea, Nirmal Robinson, Melissa R Pitman, Daniel Thomas, David Morrall Ross, Briony L Gliddon, Jason A Powell, Stuart M Pitson
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood 139 (26) (2022)
Rachel L Mynott, Craig T Wallington-Beddoe
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. ACS pharmacology & translational science 4 (3) (2021)
Krystal Bergin, Flora Yuen, Craig T Wallington-Beddoe, Anna Kalff, Shreerang Sirdesai, John Reynolds, Andrew Spencer
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. British journal of haematology 194 (3) (2021)
Craig T Wallington-Beddoe, Rachel L Mynott
Prognostic and predictive biomarker developments in multiple myeloma. Journal of hematology & oncology 14 (1) (2021)
Craig T Wallington-Beddoe, Magdalena Sobieraj-Teague, Bryone J Kuss, Stuart M Pitson
Resistance to proteasome inhibitors and other targeted therapies in myeloma. British journal of haematology 182 (1) (2018)
Craig T Wallington-Beddoe, Vicki Xie, Daochen Tong, Jason A Powell, Alexander C Lewis, Lorena Davies, Stuart M Pitson, Kenneth F Bradstock, Linda J Bendall
Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia. British journal of haematology 184 (3) (2018)